Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2435401 | 0.94 | L3MBTL3 (0.48) | HRH3L3MBTL3L3MBTL1MBTD1KDM4E | |
| SCHEMBL13207 | 0.92 | L3MBTL3 (0.46) | HRH3L3MBTL3L3MBTL1MBTD1KDM4E | |
| SCHEMBL18207732 | 0.87 | SMN1; SMN2 (0.48) | HRH3L3MBTL3L3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL16877337 | 0.87 | L3MBTL3 (0.43) | HRH3L3MBTL3L3MBTL1MBTD1KDM4E | |
| SCHEMBL14528417 | 0.87 | L3MBTL3 (0.43) | HRH3L3MBTL3L3MBTL1SMN1; SMN2MBTD1 | |
| SCHEMBL14862483 | 0.86 | SMN1; SMN2 (0.50) | HRH3L3MBTL3L3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14907095 | 0.85 | L3MBTL3 (0.49) | HRH3L3MBTL3L3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL13405621 | 0.85 | HRH3 (0.48) | HRH3L3MBTL3L3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL26008055 | 0.84 | — | — | |
| SCHEMBL21949964 | 0.84 | HTR6 (0.41) | HRH3L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872833-B2 | Adenosine receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 2005-03-29 | — | — | US | claimed |
| US-20040204584-A1 | ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-14 | — | — | US | claimed |
| WO-2016044641-A2 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2014144169-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-6872833-B2 | Adenosine receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 2005-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204584-A1 | ADENOSINE RECEPTOR LIGANDS | ADORA1, ADORA2A, ADORA3 | HRH3 575/4885L3MBTL3 4660/4885L3MBTL1 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.